For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

IDT and Beckman Coulter Life Sciences' collaboration marks a significant step forward in enabling labs to streamline oncology research workflows with enhanced precision, scalability, and ...

Improving timely access to oral oncology medications. Time to treatment initiation in NSCLC and CRC.

Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a ...

Breakthrough studies in hematopathology — including advances in genetic testing, relapse prediction and detection of hidden, disease-defining gene fusions in AML  — will be presented at the ...